US-based Avenzo Therapeutics has commenced the open-label Phase I/II trial of its cyclin-dependent kinase 4 (CDK4) selective ...

US-based Iambic Therapeutics has concluded the dose escalation phase in its multi-centre Phase I/Ib trial of a ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

"This epidermal growth factor serum helps improve ... (That's right, days.) But how? Here, human growth factors are paired with a handful of skin-loving ingredients: Peptides for collagen ...

What Is HER2-Positive Breast Cancer? HER2-positive breast cancer is when breast cancer cells have a protein receptor called human epidermal growth factor receptor 2 (HER2). Normally, this protein ...

This affordable option also includes an epidermal growth factor to ... make them using bacteria or yeast cells. Most growth factor serums use human stem cells and/or fibroblasts–both found ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...